Why Is PROCEPT BioRobotics (PRCT) Stock Down -9.00% Today?
Key Takeaways
- PROCEPT BioRobotics shares plunged approximately 9% during Tuesday's trading session, sliding from a prior close of $21.22 to around $19.31, as a wave of negative sentiment continued to batter the surgical robotics company.
- A cascade of recent analyst downgrades — including Truist Financial cutting the stock to Hold from Buy and slashing its price target to $25 from $30, and Citigroup also downgrading to Hold — has eroded investor confidence in the company's near-term growth trajectory.
- Rising competitive threats from prostate artery embolization (PAE) and a proposed Medicare reimbursement change that would boost PAE payments by 30% in ambulatory surgery centers starting in 2027 are fueling fears that Aquablation procedure volumes could face sustained headwinds.
- Elevated short interest of approximately 12-14% of the float is amplifying downward pressure, as bearish traders pile into a stock that has already lost more than 60% of its value over the past twelve months.
- The stock is testing its 52-week low of $19.35, a critical technical level that traders are watching closely for signs of either a capitulation bottom or a further breakdown.
Opening Summary
PROCEPT BioRobotics Corporation (PRCT), a surgical robotics company specializing in minimally invasive urologic procedures with its flagship AquaBeam and HYDROS Robotic Systems for treating benign prostatic hyperplasia (BPH), saw its shares tumble roughly 9% on Tuesday. The stock traded near $19.31, down sharply from Monday's closing price of $21.22, as a confluence of bearish analyst actions, mounting competitive concerns, and heavy short-selling activity weighed heavily on the name. The decline extends a brutal multi-month sell-off that has erased more than 60% of the company's market value over the past year.
Analyst Downgrade Fallout Continues to Reverberate
The most immediate driver behind today's accelerated selling appears to be the lingering impact of a series of high-profile analyst downgrades that have reshaped Wall Street's view of PRCT over the past several weeks. In early July, Truist Financial downgraded the stock to Hold from Buy and lowered its price target to $25 from $30, with analyst Richard Newitter citing falling confidence that the company can quickly re-accelerate procedure growth — the key metric underpinning the stock's valuation. Around the same time, Citigroup also moved to the sidelines with a Hold rating.
These actions followed a June downgrade from Leerink Partners, which cut PRCT to Market Perform from Outperform and reduced its price target to $29 from $31. Leerink specifically highlighted growing competitive risks from prostate artery embolization, a less invasive alternative for treating BPH, and reduced confidence in the company's near-term growth outlook. The firm also trimmed its fiscal 2026 procedure and revenue estimates below Wall Street consensus, placing them near the low end of management's guidance range.
Competitive and Reimbursement Headwinds Intensify
Beyond the analyst commentary, a tangible regulatory development has added fuel to the bearish thesis. A recent Medicare OPPS proposal would increase ambulatory surgery center payments for PAE procedures by 30% beginning in 2027. This richer reimbursement structure could tilt physician preference further toward PAE, which is already viewed as more profitable than Aquablation therapy for treating physicians, even if clinical outcomes are considered less compelling. For a company like PROCEPT BioRobotics that derives the vast majority of its revenue from Aquablation procedure volumes and associated handpiece sales, any shift in the competitive landscape toward a reimbursed alternative represents a material risk.
Compounding these external pressures, the company has been navigating internal disruption from a sales force restructuring under new leadership. CEO Larry Wood, who took the helm in September 2025, has acknowledged that the commercial realignment created "some near-term disruption," though he expressed confidence that benefits would build through the year. The market, however, appears increasingly skeptical that procedure growth can re-accelerate quickly enough to justify the company's growth narrative.
Market Context and Trading Activity
Tuesday's sell-off in PRCT was accompanied by elevated trading volume, with approximately $7.9 million in shares changing hands during the session — a sign of conviction behind the move. The decline far outpaced the broader market, with the S&P 500 and healthcare sector ETFs trading relatively flat to slightly lower on the day. The stock's beta of approximately 0.87 suggests it typically moves less than the broader market, making today's outsized drop all the more notable as a stock-specific event.
Technically, PRCT is now trading well below both its 50-day moving average of approximately $24.70 and its 200-day moving average of roughly $26.55, confirming a deeply entrenched downtrend. The stock is hovering just above its 52-week low of $19.35, a level that, if broken, could trigger another wave of technical selling. Short interest remains elevated at roughly 12-14% of the float, with days-to-cover near 4-5 days, indicating that bearish positioning is substantial and could exacerbate downward moves — or fuel a sharp snapback if positive catalysts emerge.
Trending AI Robots
In volatile market environments like the one currently affecting PRCT, traders often turn to algorithmic and AI-driven strategies to navigate price swings with discipline and speed. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, each designed to analyze thousands of stocks across varying strategies, timeframes, and performance metrics. These bots are not static — only those demonstrating the strongest real-time performance under current market conditions are featured, giving traders a dynamic view of which automated strategies are thriving right now. Whether you are looking to complement your own analysis or explore fully automated approaches, the Trending AI Robots section offers a window into how AI is being deployed to identify opportunities across the market.
What Comes Next for PRCT
Looking ahead, the near-term outlook for PRCT hinges on several key catalysts. The company's next quarterly earnings report will be closely scrutinized for evidence that procedure volumes are stabilizing or re-accelerating, and whether management reaffirms or adjusts its full-year 2026 revenue guidance of $390 million to $410 million. Any downward revision would likely trigger another leg lower, while a beat-and-raise quarter could spark a significant short-squeeze given the elevated bearish positioning.
Longer term, the fully enrolled WATER IV randomized prostate cancer trial represents a potential game-changer. Primary endpoint results are expected at the American Urological Association Annual Meeting in spring 2027, and positive data could expand Aquablation's total addressable market into prostate cancer, potentially reigniting institutional interest. However, with trial results still months away and competitive and reimbursement headwinds intensifying in the core BPH market, the stock may remain under pressure until tangible positive catalysts materialize. Traders will also be watching for any changes in PAE reimbursement policy, further analyst rating actions, and insider trading patterns for signals about management's confidence in the business.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PRCT in downward trend: 10-day moving average broke below 50-day moving average on September 21, 2026
The 10-day moving average for PRCT crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRCT as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for PRCT turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 36 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
PRCT moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for PRCT entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRCT's RSI Indicator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRCT advanced for three days, in 196 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
PRCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.905) is normal, around the industry mean (10.853). P/E Ratio (54.945) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.249) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. PRCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement